Showing results (111-120 of 165) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|May 26, 2016
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaborationChan Y Cheah, Paul J Bröckelmann, Dai Chihara, et al.
Immunity|June 21, 2005
A network of PDZ-containing proteins regulates T cell polarity and morphology during migration and immunological synapse formationMandy J Ludford-Menting, Jane Oliaro, Faruk Sacirbegovic, et al.
Blood Advances|June 12, 2023
Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphomaDiego Villa, Aixiang Jiang, Carlo Visco, et al.
Blood|April 2, 2014
Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinibChan Y Cheah, Kate Burbury, Jane F Apperley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 2025
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell LymphomaMichael Wang, David Salek, David Belada, et al.
Blood|June 11, 2024
Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed/refractory CLL: the phase 1b BRUIN trialLindsey E Roeker, Jennifer A Woyach, Chan Y Cheah, et al.
Annals of Hematology|February 3, 2026
Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trialYasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, et al.
Ejhaem|April 18, 2024
Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry projectBriony Shaw, Eliza Chung, Cameron Wellard, et al.
Haematologica|March 7, 2024
Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance studyAllison Barraclough, Shivam Agrawal, Dipti Talaulikar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesC Y Cheah, D Chihara, S Horowitz, et al.
Pageof 17